MAGNEVIST Drug Patent Profile
✉ Email this page to a colleague
When do Magnevist patents expire, and what generic alternatives are available?
Magnevist is a drug marketed by Bayer Hlthcare and is included in two NDAs.
The generic ingredient in MAGNEVIST is gadopentetate dimeglumine. There is one drug master file entry for this compound. Additional details are available on the gadopentetate dimeglumine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MAGNEVIST?
- What are the global sales for MAGNEVIST?
- What is Average Wholesale Price for MAGNEVIST?
Summary for MAGNEVIST
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 22 |
| Clinical Trials: | 30 |
| Patent Applications: | 1,327 |
| Drug Prices: | Drug price information for MAGNEVIST |
| What excipients (inactive ingredients) are in MAGNEVIST? | MAGNEVIST excipients list |
| DailyMed Link: | MAGNEVIST at DailyMed |
Recent Clinical Trials for MAGNEVIST
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Dipan Shah | N/A |
| Guerbet | N/A |
| Patricia Kim Phuong Nguyen | Phase 4 |
US Patents and Regulatory Information for MAGNEVIST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | MAGNEVIST | gadopentetate dimeglumine | INJECTABLE;INJECTION | 019596-001 | Jun 2, 1988 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bayer Hlthcare | MAGNEVIST | gadopentetate dimeglumine | INJECTABLE;INJECTION | 021037-001 | Mar 10, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MAGNEVIST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | MAGNEVIST | gadopentetate dimeglumine | INJECTABLE;INJECTION | 019596-001 | Jun 2, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Hlthcare | MAGNEVIST | gadopentetate dimeglumine | INJECTABLE;INJECTION | 019596-001 | Jun 2, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Hlthcare | MAGNEVIST | gadopentetate dimeglumine | INJECTABLE;INJECTION | 019596-001 | Jun 2, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Hlthcare | MAGNEVIST | gadopentetate dimeglumine | INJECTABLE;INJECTION | 021037-001 | Mar 10, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Hlthcare | MAGNEVIST | gadopentetate dimeglumine | INJECTABLE;INJECTION | 021037-001 | Mar 10, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MAGNEVIST
See the table below for patents covering MAGNEVIST around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 601916 | ⤷ Sign Up | |
| Netherlands | 194579 | ⤷ Sign Up | |
| France | 2590484 | SELS COMPLEXES METALLIQUES PHYSIOLOGIQUEMENT ACCEPTABLES UTILISABLES POUR DIAGNOSTIC PAR RMN | ⤷ Sign Up |
| New Zealand | 206868 | PHYSIOLOGICALLY TOLERABLE, NON-RADIOACTIVE COMPLEX SALTS AND DIAGNOSTIC COMPOSITIONS | ⤷ Sign Up |
| Ireland | 53639 | PARAMAGNETIC COMPLEX SALTS, THEIR PREPARATION, AND THEIR USE IN NMR-DIAGNOSTICS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MAGNEVIST
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0071564 | SPC/GB93/060 | United Kingdom | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
